Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

7. august 2009 oppdatert av: Massachusetts General Hospital

A Tolerability and Efficacy Study of the Angiogenesis Inhibitor Bevacizumab in Combination With 5-Fluorouracil, Oxaliplatin, and External Beam Radiation Therapy Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

The purpose of this study is determine the safety of bevacizumab, oxaliplatin, 5-FU, and gemcitabine in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating patients with locally advanced pancreatic cancer (Phase II portion).

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

  • The combination of all three drugs and radiation treatment has never been given to people before, therefore, we are going to add just one additional drug at a time for safety reasons.
  • The first group of participants (3-4) who enroll on the study will receive 5-FU, radiation therapy with the added drug oxaliplatin, this is called Regimen level 1. If these participants have few or easily manageable side effects, then another group of participants will be enrolled and will receive 5-FU, radiation, oxaliplatin with the addition of bevacizumab this is called Regimen level 2.
  • The combination of study drugs and radiation will last about 6 weeks, this 6 week period is called a cycle 1.
  • Regimen Level 1 will receive the following: oxaliplatin intravenously on days 1, 8, 15, 22, 29, and 36; 5-FU infused by a continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38; radiation therapy Monday-Friday to complete on day 38.
  • Regimen Level 2 will receive the following; bevacizumab intravenously on days 1, 15, and 29; oxaliplatin intravenously on days 1, 8, 15, 22, 29 and 36; 5-FU infused by continuous infusion days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38; radiation therapy Monday-Friday to complete on day day 38.
  • The following are tests and procedures that will be performed during cycle 1: physical examination; blood work, urine sample. perfusion CT scan on day 12 (for those participants enrolled at Massachusetts General Hospital).
  • At the end of cycle 1, CT scans will be performed to evaluate the participants disease status before they receive combination gemcitabine and bevacizumab. If the scans show the tumor has reduced in size and can be surgically removed, then surgery will be scheduled and the patient will receive gemcitabine and bevacizumab about 4 weeks after the surgery. If the scans show the tumor can not be removed, the patient will receive the gemcitabine/bevacizumab combination about 4 weeks after completing cycle 1.
  • Cycles 2-5 consist of: gemcitabine given intravenously on days 1, 8, and 15 every 28 days; bevacizumab given intravenously on days 1 and 15 every 28 days. During cycles 2-5 the following tests and procedures will be performed: physical examination including vital signs on day 1 and 15 of each cycle; blood work on days 1, 8 and 15 of each cycle; a urine sample on day 1 of each cycle; CT scans will be done every 2 cycles.
  • It will take about 7 months to complete the study treatment (longer for those who have surgery after Cycle 1).

Studietype

Intervensjonell

Registrering (Faktiske)

52

Fase

  • Fase 2
  • Fase 1

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically and radiologically confirmed locally advanced pancreatic ductal adenocarcinoma and have not received prior therapy
  • Disease is measurable by CT scan
  • Age >= to 18 years
  • Life expectancy of 4 months or longer
  • ANC >/= 1,500mm/cm3
  • Hemoglobin >/= 9g/dl
  • Platelet count >/= 100,000/cm3
  • Total bilirubin </= 2 times control
  • SGOT/SGPT </= 2.5 times upper limit of normal
  • Serum creatinine < 2mg/dl
  • No evidence of metastatic disease by laparoscopy

Exclusion Criteria:

  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk for complications
  • No secondary malignancies other than non-melanoma skin cancers or carcinoma in-situ of the cervix within past 5 years
  • Patients with pre-existing peripheral neuropathy of grade 2 or greater
  • Pregnant or lactating women
  • Current, recent (within 4 weeks of study entry) or planned participation in an experimental drug study
  • Blood pressure of >150/100 mmHg
  • Unstable angina
  • New York Heart Association Grade II or greater congestive heart failure
  • History of myocardial infarction or stroke within 6 months
  • Clinically significant peripheral vascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • Presence of central nervous system or brain metastases
  • Major surgical procedure, open biopsy,m or significant traumatic injury within 28 days prior to day 0
  • Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
  • Urine protein creatinine ratio > or = to 1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0
  • Serious, non-healing wound, ulcer, or bone fracture

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Regimen Level 1
Radiation/Oxaliplatin/5-FU
Legemiddel: bevacizumab
Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
Legemiddel: 5-Fluorouracil
Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
Legemiddel: Oxaliplatin
Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
Legemiddel: gemcitabine
Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
Fremgangsmåte: External Beam Radiation Therapy
Monday through Friday ending on day 38 of cycle 1
Eksperimentell: Regimen Level 2
Radiation/Oxaliplatin/Bevacizumab/5-FU
Legemiddel: bevacizumab
Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
Legemiddel: 5-Fluorouracil
Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
Legemiddel: Oxaliplatin
Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
Legemiddel: gemcitabine
Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
Fremgangsmåte: External Beam Radiation Therapy
Monday through Friday ending on day 38 of cycle 1

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
To determine the safety and tolerability of the combination of bevacizumab, 5-FU, oxaliplatin, and EBRT for locally advanced pancreatic cancer
Tidsramme: 2 years
2 years
to determine the survival of patients treated with this regimen.

Sekundære resultatmål

Resultatmål
Tidsramme
To determine the progression free survival
to determine the rate of conversion to resectability after treatment
Tidsramme: 2 years
2 years
to asses the duration of response and response rate of this combination and
to evaluate the toxicities.
Tidsramme: 2 years
2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Massachusetts General Hospital

Samarbeidspartnere

Sanofi
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Genentech, Inc.

Etterforskere

  • Hovedetterforsker: Lawrence S. Blaszkowsky, MD, Massachusetts General Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mai 2006

Primær fullføring (Faktiske)

1. august 2007

Studiet fullført (Faktiske)

1. juli 2009

Datoer for studieregistrering

Først innsendt

24. mars 2006

Først innsendt som oppfylte QC-kriteriene

24. mars 2006

Først lagt ut (Anslag)

28. mars 2006

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

10. august 2009

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. august 2009

Sist bekreftet

1. august 2009

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 05-233

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Bukspyttkjertelkreft

Kliniske studier på bevacizumab

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Sri Lanka

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere